{"organizations": [], "uuid": "5c5a4846e0d960ed021c831862bbb331a9193210", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bioverativ-announces-first-patient/brief-bioverativ-announces-first-patient-dosed-in-phase-3-study-of-bivv009-for-cold-agglutinin-disease-treatment-idUSFWN1QO0D6", "country": "US", "domain_rank": 408, "title": "BRIEF-Bioverativ Announces First Patient Dosed In Phase 3 Study Of BIVV009 For Cold Agglutinin Disease Treatment", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.121, "site_type": "news", "published": "2018-03-06T20:38:00.000+02:00", "replies_count": 0, "uuid": "5c5a4846e0d960ed021c831862bbb331a9193210"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-bioverativ-announces-first-patient/brief-bioverativ-announces-first-patient-dosed-in-phase-3-study-of-bivv009-for-cold-agglutinin-disease-treatment-idUSFWN1QO0D6", "ord_in_thread": 0, "title": "BRIEF-Bioverativ Announces First Patient Dosed In Phase 3 Study Of BIVV009 For Cold Agglutinin Disease Treatment", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "bioverativ inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - Bioverativ Inc:\n* BIOVERATIV ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 STUDY OF BIVV009 FOR TREATMENT OF COLD AGGLUTININ DISEASE Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T20:38:00.000+02:00", "crawled": "2018-03-06T14:50:12.008+02:00", "highlightTitle": ""}